Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

December 6, 2023 updated by: Chiti Arturo, IRCCS San Raffaele

The role of PET/CT with Choline in the restaging of prostatic disease is now universally recognized, and its use has become routine in numerous centers in Italy and abroad. The indication for the test is provided exclusively by an increase in PSA. It was interesting to understand whether these prognostic factors have an influence on the probability of detecting disease by PET with Choline to identify patients who have a greater probability of benefiting from the use of this method with the possibility of identifying the disease in earlier stages.

Study Overview

Status

Completed

Conditions

Prostate Cancer

Intervention / Treatment

Diagnostic test: Diagnostic accuracy

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Italy
- Italia
  - Milano, Italia, Italy
    - IRCCS San Raffaele

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

The study is retrospective observational and the results of the choline PET diagnostic tests of 68 patients performed at our center from 2005 to 2013 were reviewed.

Description

Inclusion Criteria:

patients operated with radical prostatectomy
patients that present biochemical recurrence of the disease;

Exclusion Criteria:

patients <18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PET/CT with Choline in the restaging of prostatic disease. Time Frame: 1 year	retrospective analysis of 68 patients with biochemical recurrence of prostase disease that performed PET/CT with choline for the restaging of the disease.	1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IRCCS San Raffaele

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2015

Primary Completion (Actual)

November 25, 2015

Study Completion (Actual)

November 25, 2015

Study Registration Dates

First Submitted

November 28, 2023

First Submitted That Met QC Criteria

December 6, 2023

First Posted (Estimated)

December 14, 2023

Study Record Updates

Last Update Posted (Estimated)